Riskpilot← Back to searchSign inGet full accessVITAMINVEIEN 1B AS
ASActiveOrg 923581561Dronning Mauds Gate 10, 0250 OsloRental and operating of own or leased real estate · NACE 6820Est. 20190 employees
Revenue 2024
NOK 2,7M
+6% vs 2023
EBITDA margin
88.2%
+5% vs 2023
Equity ratio
90.0%
Financial strength
Net profit 2024
NOK 2M
+6% vs 2023
| Revenue | NOK 2,7M | +6% |
| EBITDA | NOK 2,4M | +5% |
| Net profit | NOK 2M | +6% |
| Total assets | NOK 53,1M | +16% |
| Equity | NOK 47,8M | +17% |
| Employees | 0 | — |
Legal name
VITAMINVEIEN 1B AS
Org number
923581561
Legal form
Aksjeselskap
NACE code
6820 · Rental and operating of own or leased real estate
Founded
10. oktober 2019
Share capital
NOK 60 003
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap.
Company purpose
Investering i eiendom og alt som naturlig hører inn under dette.
Address
Dronning Mauds Gate 10, 0250 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 2 003 | 2 034 | 2 303 | 2 585 | 2 737 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 |
| EBITDA | 1 729 | 1 794 | 1 963 | 2 307 | 2 415 |
| Depreciation & amort. | −3 767 | −3 767 | −1 883 | −0 | −0 |
| EBIT | −2 038 | −1 973 | 80 | 2 307 | 2 415 |
| Net financials | −1 | −0 | −0 | 66 | 111 |
| Profit before tax | −2 039 | −1 973 | 80 | 2 373 | 2 526 |
| Tax | −449 | −434 | 17 | 522 | 556 |
| Net profit | −1 590 | −1 539 | 62 | 1 851 | 1 970 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 33 570 | 30 721 | 37 775 | 45 719 | 53 126 |
| Equity | 27 461 | 25 922 | 32 985 | 40 836 | 47 806 |
| Long-term debt | 4 826 | 4 119 | 3 812 | 3 909 | 3 998 |
| Short-term debt | 1 283 | 680 | 978 | 975 | 1 323 |
| Total debt | 6 109 | 4 798 | 4 790 | 4 884 | 5 321 |
EBITDA margin
88.2%
This company
15.8%
Market median
+458% vs market
20202024
Equity ratio
90.0%
This company
38.2%
Market median
+136% vs market
20202024
Return on equity
4.1%
This company
18.4%
Market median
-78% vs market
20202024
Net profit margin
72.0%
This company
8.1%
Market median
+789% vs market
20202024
Asset turnover
0.05×
This company
1.12×
Market median
-96% vs market
20202024
Debt / equity
0.11×
This company
0.62×
Market median
+82% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2024 | |
| Chairman | 2020 | |
| Former (1) | ||
| Board of Directors | 2020 – 2024 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Ferd As
VITAMINVEIEN 1B AS Board members of VITAMINVEIEN 1B AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ole Blaauw Johansen | Board of Directors | 0 companies |
| Camilla Krogh | Chairman | 0 companies |
| Erik Carl Rosness | Board of Directors | 0 companies |